Acme United Corp (ACU) Q2 2026 Earnings Call Highlights: Strong Sales Growth
Acme United Corp (ACU) reported Q2 2026 net sales up 16% to $63 million and net income up to $5.1 million, with EPS up 5% to $1.22. Gross margin rose to 42.6% from 41%, aided by MyMedic sales of about $4.3 million. Net debt increased to $27.3 million and free cash flow was about $15 million, while tariffs and higher SG&A weighed on results.
How this was made
The 30-second read
Why it matters
The disclosed Q2 growth and margin improvement, plus management’s tariff and expansion commentary, can drive near-term expectations for sales growth, gross margin trajectory, and leverage from the MyMedic acquisition.
Market read
Traders can update models for ACU’s growth and margin drivers (MyMedic mix, tariffs) and balance-sheet trajectory (higher net debt) based on the specific Q2 figures and management commentary.
What to watch
SG&A rose to 32% of sales due to MyMedic advertising, and net debt increased to $27.3M; traders may underweight how higher spend and leverage could pressure future free cash flow.
Background
The piece summarizes Acme United’s Q2 2026 earnings call, including reported financial metrics and CEO/CFO Q&A on MyMedic, tariffs, and capacity expansion plans.
Ticker impact
Acme United reported Q2 net sales up 16% to $63M and EPS up 5% to $1.22, with MyMedic sales contributing $4.3M.
Near-term bias modestly positive, with traders likely focusing on tariff sensitivity and leverage from the MyMedic acquisition.
The article provides multiple concrete Q2 datapoints (sales, EPS, gross margin, SG&A, net debt, free cash flow) plus management commentary on tariffs and capacity expansion, which can drive revisions to near-term margin and growth expectations.
Market effects
First aid and medical supplies peers may see read-across on how tariffs and advertising spend affect gross margin and operating leverage.
U.S. margin pressure from tariffs is explicitly cited, implying regional sensitivity for similar manufacturers.
Tariff and supply-chain disruption commentary suggests broader trade-policy risk for consumer health and medical device supply chains.
Counterpoint
Margin improvement is attributed largely to MyMedic mix, while U.S. margins fell about 100 bps from tariffs, so the quality of the gross margin trend may be less durable than it appears.
Key entities
- companyAcme United Corp
Reported Q2 2026 net sales, EPS, gross margin, SG&A, net debt, and free cash flow, and discussed MyMedic-driven growth and tariff impacts.
- executiveWalter Johnsen
CEO quoted on Spill Magic capacity expansion, MedNap throughput/compliance upgrades, and tariff-driven margin expectations.
- executivePaul Driscoll
CFO quoted on Westcott growth drivers and volume versus pricing.